New therapeutic approaches.
Clinicians have witnessed an evolution from sulfasalazine and hydrocortisone to alternative aminosalicylates and steroids. Revolutionary changes beyond these, however, and other "nonspecific" anti-immunoinflammatory compounds require clarification of the primary events either activating inflammatory cascades or preventing the down-regulation of homeopathic inflammation. The authors remain encouraged by advances in basic research pertaining to IBD and optimistic that novel empiric observations and therapeutic trials will focus bench-side investigation as clinicians strive to improve the quality of life for patients.
Hanauer
S B
SB
University of Chicago Medical Center, Illinois, USA.
Schulman
M I
MI
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000628:therapy; D011448:Prostaglandin Antagonists / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D005938:Glucocorticoids; D011448:Prostaglandin Antagonists